'Cures' resurrects orphan exclusivity; 'Dormant' protection dead?
This article was originally published in Scrip
Executive Summary
Patient advocates lavished quick praise on lawmakers for including a measure in the latest version of the 21st Century Cures Act, unveiled on 13 May, which would extend by six months the exclusivity protection for marketed drugs that seek and gain new indications aimed at preventing, diagnosing or treating rare diseases or conditions.